434 results on '"Uharek, Lutz"'
Search Results
102. Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation.
103. Conditioning with Treosulfan and Cyclophosphamide without Application of Antibodies in MHC Mismatch Transplantations in Mice.
104. Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.
105. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell–depleted reduced-intensity transplantation
106. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells
107. WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia.
108. CMV-Seropositive Patients Allografted with a CMV-Seronegative Donor Show Delayed or Missing CMV-Specific T-Cell Immune Response and Are at Higher Risk for CMV-Viremia and CMV-Disease.
109. Preemptive Transfer of GMP-Grade CD8-Depleted Donor Lymphocytes after T-Cell Depleted Reduced-Intensity Transplantation.
110. WT1-Specific T Cell Responses Are Frequent after Allogeneic Stem Cell Transplantation for Acute and Chronic Myeloid Leukemia.
111. Quantification and Characterization of Peripheral Blood Natural Killer (NK) Cells Mediating Rituximab and Alemtuzumab Dependent Cytotoxicity.
112. Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study.
113. Therapeutic spectrum in the treatment of myelodysplastic syndromes
114. Granulocyte-Colony-Stimulating Factor (G-CSF) Accelerates Normal Myeloid Recovery More Efficiently in Patients with Favorable Than with Intermediate or Unfavorable Cytogenetic Risk Acute Myeloid Leukemias (AML): A Retrospective Analysis of the East German Hematology Oncology Study Group (OSHO).
115. Real-Time Quantitative Y Chromosome Specific PCR vs. XY-FISH vs. Fluorescent STR-PCR for Chimerism Analysis after Allogeneic Sex-Mismatched PBSCT.
116. Lymphoma Cells Are Highly Sensitive to Cytotoxic T-Cell-Killing Despite Presence of Multiple Resistance Mechanisms
117. Analysis of Factors Influencing Natural Killer (NK) Cell Activity during the Early Phase after Allogeneic Stem Cell Transplantation (SCT)
118. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model
119. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice
120. Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect
121. Allogeneic Peripheral Blood Progenitor Cells: Current Status and Future Directions
122. ALLOGENEIC NK CELLS AS POTENT ANTILEUKEMIC EFFECTOR CELLS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION IN MICE
123. MHC-Associated and MHC-lndependent Urinary Chemosignals in Mice Are Expressed via the Hematopoietic System
124. The Hematopoietic System Influences Odor Specificity in Mice and Rats
125. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
126. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
127. TP53, SF3B1, and NOTCH1mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
128. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell–depleted reduced-intensity transplantation
129. Mucosal FOXP3+regulatory T cells are numerically deficient in acute and chronic GvHD
130. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD
131. Mucosal Foxp3+ Regulatory T Cells Show Significant Numerical Differences in Patients with Intestinal Graft-Versus-Host Disease Compared to Infectious Diseases of the Gut.
132. Mechanisms of perforin resistance: the differentiation between perforin binding and perforin-mediated lysis remains difficult
133. DEGRANULATION OF T CELLS SPECIFIC FOR HUMAN CYTOMEGALOVIRUS (CMV) PROTEINS PP65 AND IE1 IS NOT DISTURBED IN TRANSPLANT PATIENTS.
134. Air embolism simulating atypical pneumonia.
135. SF3B1, NOTCH1and TP53Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial
136. Influence of Cell Dose and Graft-Versus-Host Reactivity on Rejection Rates After Allogeneic Bone Marrow Transplantation
137. Frequency and Relevance of CD10+CD19+Hematogones after Allogeneic Stem Cell Transplantation.
138. Mucosal Foxp3+Regulatory T Cells Show Significant Numerical Differences in Patients with Intestinal Graft-Versus-Host Disease Compared to Infectious Diseases of the Gut.
139. Association between low uric acid levels and acute graft-versus-host disease.
140. Immunotherapy: opportunities, risks and future perspectives.
141. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells.
142. Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma.
143. Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach.
144. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.
145. Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions--A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group.
146. Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation.
147. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease.
148. Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation
149. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft- versus-host disease.
150. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte–macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.